Edition:
United Kingdom

Egalet Corp (EGLT.OQ)

EGLT.OQ on NASDAQ Stock Exchange Global Market

0.72USD
23 Feb 2018
Change (% chg)

$0.01 (+0.85%)
Prev Close
$0.71
Open
$0.71
Day's High
$0.72
Day's Low
$0.68
Volume
69,913
Avg. Vol
261,129
52-wk High
$5.58
52-wk Low
$0.68

Select another date:

Fri, Feb 23 2018

BRIEF-Egalet Says Received Notice From Teva Pharmaceuticals USA Of ANDA Submission For Approval To Market Generic Version Of Arymo ER Extended-Release Tablets

* EGALET - CO, UNIT RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA OF ANDA SUBMISSION FOR APPROVAL TO MARKET GENERIC VERSION OF ARYMO ER EXTENDED-RELEASE TABLETS

BRIEF-Broadfin Capital Reports 9.99 Pct Passive Stake In Egalet Corp

* BROADFIN CAPITAL LLC REPORTS A 9.99 PCT PASSIVE STAKE IN EGALET CORP AS OF DEC 27, 2017 - SEC FILING Source text: (http://bit.ly/2lRMZcH) Further company coverage:

BRIEF-Egalet Partners With Orapharma To Co-Promote Sprix Nasal Spray

* EGALET PARTNERS WITH ORAPHARMA TO CO-PROMOTE SPRIX® NASAL SPRAY

BRIEF-Egalet Reduces Announces Refinancing Of Existing Convertible Notes

* EGALET REDUCES DEBT OBLIGATION, EXTENDS MATURITY AND LOWERS ANNUAL INTEREST PAYMENTS THROUGH REFINANCING OF EXISTING CONVERTIBLE NOTES

BRIEF-Egalet Receives FDA Tentative Approval For Chronic Pain Treatment Drug

* EGALET RECEIVES FDA TENTATIVE APPROVAL FOR EXPANDED LABEL FOR ARYMO® ER (MORPHINE SULFATE) C-II, AN EXTENDED-RELEASE MORPHINE PRODUCT FORMULATED WITH ABUSE-DETERRENT PROPERTIES FOR TREATMENT OF CHRONIC PAIN

BRIEF-Egalet Says Notified Verbally By CVS Caremark That Sprix Will No Longer Be On Formulary For A Portion Of Commercial Covered Lives Beginning 2018

* EGALET - NOTIFIED VERBALLY BY CVS CAREMARK THAT SPRIX WILL NO LONGER BE ON FORMULARY FOR A PORTION OF COMMERCIAL COVERED LIVES BEGINNING JAN 1, 2018

BRIEF-Egalet Corp's Phase 3 Study Of Egalet-002 In Patients With Moderate-To-Severe Chronic Low Back Pain Meets Primary Endpoint​

* EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF EGALET-002 IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN

BRIEF-Egalet Corp Says ‍Apotex Has Lost Right To Launch An Authorized Generic Version Of Sprix Nasal Spray​

* EGALET CORP - ‍COMPANY DID NOT RECEIVE ANY WRITTEN NOTIFICATION ON OR BEFORE NOTIFICATION DEADLINE FOR PRODUCT LAUNCH FROM APOTEX CORP & APOTEX INC​

BRIEF-EGALET ANNOUNCES LATE-STAGE STUDY DATA ON EGALET-002

* EGALET ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 SAFETY STUDY EVALUATING SAFETY OF EGALET-002

BRIEF-Egalet announces ARYMO ER added to large payer Medicare Part D Formulary

* A large payer will provide coverage of ARYMO ER extended-release tablets for oral use -CII for its Medicare Part D Members​

Select another date: